Overactive bladder syndrome: Is a request for a dose increase indicative of more severe symptoms? Results from a randomised, double-blind, placebo-controlled, risfng-dose study of solifenacin (SUNRISE)
Авторы
Cardozo L. ,
Avdoshin V. ,
Wolski Z. ,
Pavlik I. ,
Sofras F.E. ,
Toth Z. ,
Vasco P.M. ,
Drogendijk T. ,
Wright D.M. ,
Bolodeoku J.